|By PR Newswire||
|February 27, 2014 07:00 PM EST||
SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
The live presentation takes place on Tuesday, March 4 at 9:20am ET (6:20am PT). The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.
Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.
Aug. 30, 2016 09:08 AM EDT
Aug. 30, 2016 08:45 AM EDT Reads: 902
Aug. 30, 2016 05:45 AM EDT Reads: 2,459
Aug. 30, 2016 03:45 AM EDT Reads: 504
Aug. 30, 2016 02:30 AM EDT Reads: 1,861
Aug. 30, 2016 02:00 AM EDT Reads: 2,245
Aug. 30, 2016 01:30 AM EDT Reads: 3,052
Aug. 30, 2016 01:15 AM EDT Reads: 2,358
Aug. 30, 2016 01:00 AM EDT Reads: 1,940
Aug. 30, 2016 12:00 AM EDT Reads: 1,675
Aug. 29, 2016 10:00 PM EDT Reads: 2,494
Aug. 29, 2016 08:30 PM EDT Reads: 2,452
Aug. 29, 2016 08:15 PM EDT Reads: 1,880
Aug. 29, 2016 08:00 PM EDT Reads: 928
Aug. 29, 2016 07:00 PM EDT Reads: 1,988